These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 33134073)

  • 1. A case of simultaneous occurrence of hepatitis and pancreatitis during the combination immunochemotherapy for non-small cell lung carcinoma.
    Tanaka S; Asakawa R; Komuta K; Tanizaki S; Kanai T; Kuroyama M; Shimazu K; Uchida J; Yakushijin T; Ueno K
    Respir Med Case Rep; 2020; 31():101266. PubMed ID: 33134073
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Immune thrombocytopenia in a small cell lung cancer patient treated with atezolizumab: a case report.
    Qiu G; Li S; Li B; Yang Q; Deng H; Yang Y; Xie X; Lin X; Seki N; Miura S; Shukuya T; Zhou C; Liu M
    Transl Lung Cancer Res; 2022 Nov; 11(11):2346-2355. PubMed ID: 36519029
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Peripheral Blood Markers Identify Risk of Immune-Related Toxicity in Advanced Non-Small Cell Lung Cancer Treated with Immune-Checkpoint Inhibitors.
    Pavan A; Calvetti L; Dal Maso A; Attili I; Del Bianco P; Pasello G; Guarneri V; Aprile G; Conte P; Bonanno L
    Oncologist; 2019 Aug; 24(8):1128-1136. PubMed ID: 31015312
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Association Between Immune-related Adverse Events and Efficacy of Immune Checkpoint Inhibitors in Non-small-cell Lung Cancer.
    Grangeon M; Tomasini P; Chaleat S; Jeanson A; Souquet-Bressand M; Khobta N; Bermudez J; Trigui Y; Greillier L; Blanchon M; Boucekine M; Mascaux C; Barlesi F
    Clin Lung Cancer; 2019 May; 20(3):201-207. PubMed ID: 30442524
    [TBL] [Abstract][Full Text] [Related]  

  • 5. PD-1/PD-L1 Blockade Therapy in Advanced Non-Small-Cell Lung Cancer: Current Status and Future Directions.
    Xia L; Liu Y; Wang Y
    Oncologist; 2019 Feb; 24(Suppl 1):S31-S41. PubMed ID: 30819829
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immune-Related Multiple-Organs Injuries Following ICI Treatment With Tislelizumab in an Advanced Non-Small Cell Lung Cancer Patient: A Case Report.
    Deng C; Yang M; Jiang H; Wang R; Yang Z; Sun H; Cui H
    Front Oncol; 2021; 11():664809. PubMed ID: 34540659
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The association between tumor burden and severe immune-related adverse events in non-small cell lung cancer patients responding to immune-checkpoint inhibitor treatment.
    Sakata Y; Kawamura K; Ichikado K; Shingu N; Yasuda Y; Eguchi Y; Anan K; Hisanaga J; Nitawaki T; Iio M; Sekido Y; Nakano A; Sakagami T
    Lung Cancer; 2019 Apr; 130():159-161. PubMed ID: 30885338
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discontinuation due to immune-related adverse events is a possible predictive factor for immune checkpoint inhibitors in patients with non-small cell lung cancer.
    Komiya K; Nakamura T; Abe T; Ogusu S; Nakashima C; Takahashi K; Kimura S; Sueoka-Aragane N
    Thorac Cancer; 2019 Sep; 10(9):1798-1804. PubMed ID: 31328416
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of a combination of chemotherapy and immune checkpoint inhibitors and immune checkpoint inhibitors alone for the treatment of advanced and metastatic non-small cell lung cancer.
    Kuo CS; Wang CC; Huang YC; Pavlidis S; Liu CY; Ko HW; Chung FT; Lin TY; Wang CL; Guo YK; Yang CT
    Thorac Cancer; 2019 May; 10(5):1158-1166. PubMed ID: 30950239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Case Report: A Squamous Cell Lung Carcinoma Patient Who Responded to Neoadjuvant Immunochemotherapy but Died From Anastomosis Leakage or/and irAEs: Immune Microenvironment and Genomic Features Changes.
    Hao L; Hu Y; Hu J; Liu Y; Mao B; Chen H; Gong X; Wang D; Wang L; Wang D
    Front Oncol; 2021; 11():674328. PubMed ID: 34367960
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Differences in the Safety and Tolerability of Immune Checkpoint Inhibitors as Treatment for Non-Small Cell Lung Cancer and Melanoma: Network Meta-Analysis and Systematic Review.
    Chai QQ; Du JY; Zhu J; Wu B
    Front Pharmacol; 2019; 10():1260. PubMed ID: 31708783
    [No Abstract]   [Full Text] [Related]  

  • 12. Diagnosis and Management of Immune Checkpoint Inhibitor-Associated Neurologic Toxicity: Illustrative Case and Review of the Literature.
    Reynolds KL; Guidon AC
    Oncologist; 2019 Apr; 24(4):435-443. PubMed ID: 30482825
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect and safety of immune checkpoint inhibitor rechallenge in non-small cell lung cancer.
    Watanabe H; Kubo T; Ninomiya K; Kudo K; Minami D; Murakami E; Ochi N; Ninomiya T; Harada D; Yasugi M; Ichihara E; Ohashi K; Fujiwara K; Hotta K; Tabata M; Maeda Y; Kiura K
    Jpn J Clin Oncol; 2019 Aug; 49(8):762-765. PubMed ID: 31090906
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment.
    Okuno T; Nakashima K; Mitarai Y; Kataoka M; Tobita H; Nagase M; Isobe T; Tsubata Y
    Respir Med Case Rep; 2022; 40():101753. PubMed ID: 36217354
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment.
    Okuno T; Nakashima K; Mitarai Y; Kataoka M; Tobita H; Nagase M; Isobe T; Tsubata Y
    Respir Med Case Rep; 2022; 40():101773. PubMed ID: 36408484
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pneumonitis, appendicitis, and biliary obstruction during toripalimab treatment in a patient with extensive-stage small-cell lung cancer: a case report.
    Qu Y; Wang Z; Feng J; Wang L; Liu H; Liu D; Zhao Y; Yu R; Li W; Sun D; Yu H
    Ann Palliat Med; 2021 Aug; 10(8):9267-9275. PubMed ID: 34488412
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endocrine toxicity of immune checkpoint inhibitors: a real-world study leveraging US Food and Drug Administration adverse events reporting system.
    Zhai Y; Ye X; Hu F; Xu J; Guo X; Zhuang Y; He J
    J Immunother Cancer; 2019 Nov; 7(1):286. PubMed ID: 31694698
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma.
    Teixidor E; Sais E; Vásquez CA; Carbajal W; Hernández A; Sánchez G; Izquierdo A; Verdura S; Menéndez JA; Bosch-Barrera J
    Oncotarget; 2018 Aug; 9(68):33043-33049. PubMed ID: 30250648
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of immune-related adverse events on survival in patients with advanced non-small cell lung cancer treated with nivolumab: long-term outcomes from a multi-institutional analysis.
    Ricciuti B; Genova C; De Giglio A; Bassanelli M; Dal Bello MG; Metro G; Brambilla M; Baglivo S; Grossi F; Chiari R
    J Cancer Res Clin Oncol; 2019 Feb; 145(2):479-485. PubMed ID: 30506406
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab.
    Sato K; Akamatsu H; Murakami E; Sasaki S; Kanai K; Hayata A; Tokudome N; Akamatsu K; Koh Y; Ueda H; Nakanishi M; Yamamoto N
    Lung Cancer; 2018 Jan; 115():71-74. PubMed ID: 29290265
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.